Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202
18 Years
N/A
Both
Lymphoma, Solid Tumor
Trial Information
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202
OBJECTIVES:
- Evaluate the effect of in vivo aflibercept on the presence of different populations of
dendritic cells (DC) and immature cells (ImC) in the peripheral blood of cancer
patients by characterizing the time course (kinetics) of the improvement in antigen
presenting cell (APC) phenotype (decline in DC/ImC ratio) occurring early and late
after aflibercept administration.
- Evaluate the effect of aflibercept administration on DC function based on ability to
stimulate antigen specific proliferative (allogeneic and tetanus toxoid) and cytolytic
T cell responses (influenza) by characterizing the time course (kinetics) of the
improvement in APC function occurring early and late after aflibercept administration.
- Explore the relationship of baseline aflibercept level and host APC phenotype.
OUTLINE: This is a multicenter study.
Patients undergo phlebotomy and blood collection at baseline and on days 15, 29, and 57.
Samples are analyzed for dendritic cell phenotype, subpopulations, maturation status, and
function in terms of ability to activate autologous T cells.
Inclusion Criteria:
- Diagnosis of advanced solid tumor or non-Hodgkin lymphoma and enrolled on clinical
trial VGFT-ST-0202
- Hemoglobin ≥ 10 g/dL
- Willing to undergo phlebotomy
Exclusion Criteria:
- none listed
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Effect of in vivo aflibercept on the presence of different populations of dendritic cells (DC) and immature cells (ImC)
Outcome Time Frame:
at days 15, 29 and 64
Safety Issue:
No
Principal Investigator
Jeffrey A. Sosman, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Vanderbilt-Ingram Cancer Center
Authority:
United States: Federal Government
Study ID:
VICC PHI0433
NCT ID:
NCT00896662
Start Date:
January 2005
Completion Date:
August 2008
Related Keywords:
- Lymphoma
- Solid Tumor
- unspecified adult solid tumor, protocol specific
- recurrent adult Burkitt lymphoma
- stage IV adult Burkitt lymphoma
- recurrent adult diffuse large cell lymphoma
- recurrent adult diffuse mixed cell lymphoma
- recurrent adult diffuse small cleaved cell lymphoma
- stage IV adult diffuse large cell lymphoma
- stage IV adult diffuse mixed cell lymphoma
- stage IV adult diffuse small cleaved cell lymphoma
- recurrent adult immunoblastic large cell lymphoma
- stage IV adult immunoblastic large cell lymphoma
- recurrent adult lymphoblastic lymphoma
- stage IV adult lymphoblastic lymphoma
- recurrent grade 1 follicular lymphoma
- recurrent grade 2 follicular lymphoma
- recurrent grade 3 follicular lymphoma
- stage IV grade 1 follicular lymphoma
- stage IV grade 2 follicular lymphoma
- stage IV grade 3 follicular lymphoma
- recurrent mantle cell lymphoma
- stage IV mantle cell lymphoma
- recurrent marginal zone lymphoma
- splenic marginal zone lymphoma
- stage IV marginal zone lymphoma
- nodal marginal zone B-cell lymphoma
- extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
- recurrent small lymphocytic lymphoma
- stage IV small lymphocytic lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, Large-Cell, Immunoblastic
Name | Location |
|---|
